In addition, tumour expression of TFF3 mRNA predicts a worse survival outcome in ER+ patients treated with tamoxifen and increased expression of TFF3 both reduces sensitivity of ER+ MC cells to tamoxifen and mediates acquired resistance to tamoxifen [14]. Here, TFF3 is linked to neoplasm.